The company’s lead asset, IBTROZI, generated $23.2 million in net product revenue during the quarter. According to data from IQVIA, the treatment has become the most prescribed ROS1 tyrosine kinase inhibitor for new patient starts in 2026. Roughly 85% of the 160 new patients identified in the second quarter were TKI-naïve, marking a 30% increase over the previous quarter. Nuvation Bio maintains a strong liquidity position, reporting $661 million in cash and marketable securities as of June 30, 2026.

Beyond its commercial efforts, the firm is aggressively advancing its pipeline, particularly with the IDH1 inhibitor safusidenib. Positive long-term Phase 2 data for the drug has prompted the company to launch new clinical studies for IDH1-mutant glioma, including a pivotal Phase 3 trial. CEO David Hung noted that the company is aiming to address broad patient populations across the spectrum of this disease. Despite the revenue growth, operating costs remain high, with research and development expenses reaching $30.7 million as the company funds its expanded clinical development programs.